# Voluven® in Paediatric Patients

> **NCT00860405** · PHASE4 · COMPLETED · sponsor: **Fresenius Kabi** · enrollment: 61 (actual)

## Conditions studied

- Cardiac Surgery
- Cardiopulmonary Bypass

## Interventions

- **DRUG:** HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)
- **DRUG:** Human serum albumin (HSA 50g/L)

## Key facts

- **NCT ID:** NCT00860405
- **Lead sponsor:** Fresenius Kabi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-08
- **Final completion:** 2010-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00860405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00860405, "Voluven® in Paediatric Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00860405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*